AMERICAN REGENT, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1967-01-01
- Employees
- 501
- Market Cap
- -
OrthoTrophix Launches Phase 2b Trial of TPX-100 for Knee Osteoarthritis with Disease-Modifying Potential
• OrthoTrophix has initiated a Phase 2b clinical trial of TPX-100, a potential disease-modifying osteoarthritis drug (DMOAD) for patients with mild to severe knee osteoarthritis in the United States.
• Previous Phase 2a results showed TPX-100 significantly improved knee function and reduced structural deterioration in subchondral bone compared to placebo, addressing a key predictor of disease progression.
• The 53-week study aims to confirm both symptomatic improvements and structural effects, potentially representing a breakthrough in knee OA treatment beyond symptom management.
© Copyright 2025. All Rights Reserved by MedPath